Annotation Detail for ZBTB2
Basic Information
Top
| Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
|---|
| C075773 |
4-phenylbutyric acid |
4-phenylbutyric acid results in decreased expression of ZBTB2 mRNA | decreases expression | 14583596
|
| D015123 |
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide |
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of ZBTB2 mRNA | decreases expression | 19150397
|
| D016572 |
Cyclosporine |
Cyclosporine results in increased expression of ZBTB2 mRNA | increases expression | 20106945
|
| C006253 |
pirinixic acid |
[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of ZBTB2 mRNA | affects binding|decreases expression|increases activity | 19710929
|
| Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
|---|
| MESH:D055371 |
Acute Lung Injury |
|
pirinixic acid |
3.58 | 18653653 |
| MESH:D018248 |
Adenoma, Liver Cell |
|
pirinixic acid |
4.11 | 16434500 |
| MESH:D001778 |
Blood Coagulation Disorders |
|
pirinixic acid |
3.57 | 19483382 |
| MESH:D002471 |
Cell Transformation, Neoplastic |
|
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide |
7.44 | 20889678 |
| MESH:D002471 |
Cell Transformation, Neoplastic |
|
Cyclosporine |
7.44 | 12371664 |
| MESH:D002779 |
Cholestasis |
|
Cyclosporine |
8.74 | 19486331 |
| MESH:D002779 |
Cholestasis |
|
pirinixic acid |
8.74 | 19176532 |
| MESH:D003876 |
Dermatitis, Atopic |
|
pirinixic acid |
2.57 | 18249437 |
| MESH:D004487 |
Edema |
|
pirinixic acid |
2.90 | 12083418 |
| MESH:D004938 |
Esophageal Neoplasms |
|
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide |
2.15 | 20426865 |
| MESH:D005234 |
Fatty Liver |
|
Cyclosporine |
9.01 | 19224547 |
| MESH:D005234 |
Fatty Liver |
|
pirinixic acid |
9.01 | 20131406 19236843 |
| MESH:D005355 |
Fibrosis |
|
Cyclosporine |
3.70 | 12168785 12639820 |
| MESH:D005885 |
Gingival Hyperplasia |
|
Cyclosporine |
4.85 | 8708960 |
| MESH:D006333 |
Heart Failure |
|
pirinixic acid |
2.76 | 20558911 |
| MESH:D006457 |
Hemoglobinuria, Paroxysmal |
|
Cyclosporine |
5.05 | 15720958 |
| MESH:D006529 |
Hepatomegaly |
|
pirinixic acid |
3.55 | 18467677 19176532 19772884 16221962 |
| MESH:D006943 |
Hyperglycemia |
|
pirinixic acid |
3.58 | 20558911 |
| MESH:D006973 |
Hypertension |
|
Cyclosporine |
2.21 | 10903974 |
| MESH:D007333 |
Insulin Resistance |
|
pirinixic acid |
2.87 | 16306350 |
| MESH:D007638 |
Keratoconjunctivitis Sicca |
|
Cyclosporine |
5.16 | 15604871 |
| MESH:D007674 |
Kidney Diseases |
|
Cyclosporine |
2.54 | 8314463 10903974 18776723 |
| MESH:D007680 |
Kidney Neoplasms |
|
Cyclosporine |
3.08 | 12371664 |
| MESH:D008106 |
Liver Cirrhosis, Experimental |
|
pirinixic acid |
1.35 | 15474484 |
| MESH:D008113 |
Liver Neoplasms |
|
pirinixic acid |
1.93 | 20007298 16377806 15890375 |
| MESH:D008664 |
Metal Metabolism, Inborn Errors |
|
Cyclosporine |
5.51 | 16801185 |
| MESH:D009135 |
Muscular Diseases |
|
pirinixic acid |
4.07 | 16239165 |
| MESH:D009203 |
Myocardial Infarction |
|
pirinixic acid |
2.27 | 19151258 |
| MESH:D015428 |
Myocardial Reperfusion Injury |
|
pirinixic acid |
3.25 | 16411023 |
| MESH:D009369 |
Neoplasms |
|
4-phenylbutyric acid |
5.95 | 19116145 |
| MESH:D009369 |
Neoplasms |
|
pirinixic acid |
5.95 | 17405874 |
| MESH:D009402 |
Nephrosis, Lipoid |
|
Cyclosporine |
5.16 | 17954296 |
| MESH:D009404 |
Nephrotic Syndrome |
|
Cyclosporine |
3.65 | 19348381 18481113 |
| MESH:D009765 |
Obesity |
|
pirinixic acid |
1.88 | 20558911 |
| MESH:D011230 |
Precancerous Conditions |
|
Cyclosporine |
3.59 | 12371664 |
| MESH:D011565 |
Psoriasis |
|
Cyclosporine |
2.33 | 16882103 |
| MESH:D015427 |
Reperfusion Injury |
|
pirinixic acid |
2.55 | 19058328 |
| MESH:D014605 |
Uveitis |
|
Cyclosporine |
4.71 | 1336536 |
| MESH:D014985 |
Xerophthalmia |
|
Cyclosporine |
5.16 | 17120751 |
Related Pathway Information